Atai Life Sciences Valuation

Is ATAI N undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ATAI N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATAI N's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATAI N's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATAI N?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ATAI N. This is calculated by dividing ATAI N's market cap by their current preferred multiple.
What is ATAI N's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$208.07m

ATAI N key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	376.5x
Enterprise Value/EBITDA	-1.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ATAI N's PB Ratio compare to its peers?

The above table shows the PB ratio for ATAI N vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	11.2x
LAB B Genomma Lab Internacional. de	2.2x	20.0%	Mex$24.1b
CRDL Cardiol Therapeutics	13.2x	36.8%	CA$203.7m
RANI Rani Therapeutics Holdings	26.4x	25.2%	US$132.0m
6634 Sinew Pharma	3.1x	n/a	NT$3.9b
ATAI N Atai Life Sciences	1.2x	35.4%	Mex$208.1m

Price-To-Book vs Peers: ATAI N is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (10.9x).

Price to Earnings Ratio vs Industry

How does ATAI N's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: ATAI N is good value based on its Price-To-Book Ratio (1.2x) compared to the Global Pharmaceuticals industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ATAI N's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATAI N PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATAI N's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.